Aclaris rises as inflammation drug shows promise in early trial

Shares of drug developer Aclaris Therapeutics ACRS.O rise 2.3% to $2.71 premarket

Co says its experimental drug ATI-052 showed promising safety and effectiveness in an early-stage clinical trial

ATI-052 aims to treat atopic dermatitis, or eczema, and asthma by blocking inflammation signals - ACRS

Co says drug was well tolerated, with mild side effects such as temporary redness at injection site

ATI-052 stayed in body for 26 days, and may allow dosing once every three months - ACRS

Co plans proof-of-concept trials early this year; larger mid-stage trial in second half of 2026

As of last close, ACRS up ~44% over the past year